FDA approves the signos glucose monitoring for weight loss
Woman with signos portable and app
Source: Signos
On Wednesday, the Food and Drug Administration approved the first glucose monitoring system especially for weight loss from the start-up signos and set a new option for Americans to manage their weight.
Current treatment options for losing-weight medication such as GLP-1S and surgical intervention are typically limited to patients with obesity or a certain BMI. Obk. Novo Nordisk‘s Wegovy and Eli Lilly“S zepbound can also be difficult to access due to their high costs, limited US insurance protection and a limited offer.
Now every patient can buy a signos membership to access their system. It uses a AI Dexcom To offer personalized data and lifestyle recommendations in real time for weight management.
“There is now a solution with which everyone can help to reduce weight, and they do not have to be a certain number of pounds to use them. It is available for the average American they need,” said Sharam Fouladgar-Mercer, co-founder and CEO of Signos, in an interview on Tuesday before the consent. “The average person may have five pounds to lose, or others may have £ 100. We are here to help you on this trip at all times.”
According to Centers for Disease Control and prevention data, the US health system of obesity Epidemic costs more than $ 170 billion a year a year. Almost 74% of the Americans are overweight or obese, it says in government data. Signos hopes that a real dent in this curve can make it for the improvement of many of us, “said Fouladgar-Mercer.
Customers who register for signos can choose a three-month or six-month plan that currently costs $ 139 or $ 129. The company will send all CGMS that a patient needs for the number of months in the plan you have selected.
The insurers are currently not covering the system for weight management, but the plans are a fraction of the monthly price of around $ 1,000 for GLP-1 in the US Signos, which work with health insurance companies and employers in order to receive cover for the system, the company said in a statement to CNBC. Signos said that “this would be expected to develop quickly, as interest in combating the weight will be expanded.”
The Signos system can be used in combination with GLP-1S or bariatric surgery, said fouladgar-Mercer. He said that patients can also use the system after being switched off by a GLP-1 to maintain their weight loss.
CGMS are small sensors that are worn on the upper arm and track the glucose levels, mainly for people with diabetes. This data is sent wirelessly to Signos’ app, which means that patients can also log their food and training levels that use the AI platform to testify recommendations.
The system not only helps people help people lose pounds, but to help users understand how their body reacts to certain foods and exercise patterns and carry out the correct changes in behavior in order to manage and maintain their weight in the long term.
Signos did not say how many patients are currently using their glucose monitoring system, but fouladgar-Mercer said tens of thousands of people had already tried it over time. He said Signos had reduced his CGM inventory and software capacity in order to edit a fairly massive scale after approval.
